Caribou Biosciences Inc
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapse… Read more
Caribou Biosciences Inc (CRBU) - Total Liabilities
Latest total liabilities as of December 2025: $57.46 Million USD
Based on the latest financial reports, Caribou Biosciences Inc (CRBU) has total liabilities worth $57.46 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Caribou Biosciences Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Caribou Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Caribou Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Caribou Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Huaiji Dengyun Auto-parts Holding Co Ltd
SHE:002715
|
China | CN¥369.03 Million |
|
Beijing Dalong Weiye Real Estate Development Co Ltd
SHG:600159
|
China | CN¥1.45 Billion |
|
Tourism Finance Corporation of India Limited
NSE:TFCILTD
|
India | ₹10.59 Billion |
|
Jiangxi Selon Industrial Co Ltd
SHE:002748
|
China | CN¥994.79 Million |
|
InnovAge Holding Corp
NASDAQ:INNV
|
USA | $234.47 Million |
|
OmniAb Inc.
NASDAQ:OABI
|
USA | $32.25 Million |
|
MedinCell S.A
PINK:MDCLF
|
USA | $105.41 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Caribou Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Caribou Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Caribou Biosciences Inc (2019–2025)
The table below shows the annual total liabilities of Caribou Biosciences Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $53.19 Million | -11.88% |
| 2024-12-31 | $60.36 Million | -5.40% |
| 2023-12-31 | $63.81 Million | -12.46% |
| 2022-12-31 | $72.89 Million | +33.67% |
| 2021-12-31 | $54.53 Million | -8.33% |
| 2020-12-31 | $59.48 Million | +9.20% |
| 2019-12-31 | $54.47 Million | -- |